Literature DB >> 29096389

Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.

Ming Chang1, Katrin Steinmetzer2, Dana N Raugi3, Robert A Smith3, Selly Ba4, Fatima Sall4, Moussa Seydi4, Alassane Niang5, ElHadji Ibrahima Sall5, Ousseynou Cisse5, Katja Rödel2, Robert W Coombs6, Geoffrey S Gottlieb7.   

Abstract

BACKGROUND: The Alere q HIV-1/2 Detect test (Alere Detect) is a rapid point-of-care (POC) nucleic acid test (NAT) that can detect and differentiate HIV-1 and HIV-2 in 25-μL whole blood or plasma samples. The Alere Detect test has been validated for early infant diagnosis of HIV-1 infection, and it is the only POC NAT device currently known to detect HIV-2, which is endemic in West Africa.
OBJECTIVES: To evaluate the sensitivity detecting HIV-2 RNA and the differential performance of the Alere Detect. STUDY
DESIGN: Plasma samples from non-HIV (n=4), HIV-1 (n=22), HIV-2 (n=111; 29 Group A, 2 Group B) and HIV-1/HIV-2 dually-seropositive (n=8) participants in Senegal and the United States and HIV-2 reference strains (3 Group A, 1 Group B) were tested by Alere Detect, Abbott RealTime HIV-1 and the University of Washington HIV-2 RNA quantitative (UW HIV-2) assays.
RESULTS: The Alere Detect correctly differentiated between HIV-1 and HIV-2 in all 80 (100%) patient samples with detectable HIV RNA (n=20 HIV-1, 60 HIV-2). The overall HIV-2 detection concordance between Alere Detect and the UW HIV-2 assay was 68% (54/80); the concordance improved to 100% (30/30) for samples with HIV-2 RNA >300copies/mL. Neither assay detected HIV-2 RNA in 31 of 111 HIV-2 seropositive samples.
CONCLUSIONS: The Alere Detect test is a novel device detecting HIV RNA in clinical samples, and differentiating HIV-1 and HIV-2 with a high level of specificity. It has the potential for use as a rapid HIV-2 NAT-based diagnosis tool in resource-limited settings and to confirm HIV-2 infection for the CDC 4th generation HIV-1/2 diagnostic algorithm.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alere q HIV-1/2 Detect; Diagnosis; HIV-2; Nucleic acid test; Point-of-care; Qualitative

Mesh:

Substances:

Year:  2017        PMID: 29096389      PMCID: PMC5700839          DOI: 10.1016/j.jcv.2017.10.013

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  25 in total

1.  Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa.

Authors:  Lesley Scott; Natasha Gous; Sergio Carmona; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2015-03-04       Impact factor: 5.948

2.  HIV-2 Infection Surveillance--United States, 1987-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-07-29       Impact factor: 17.586

3.  Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.

Authors:  Agnès Gautheret-Dejean; Jonathan Bocobza; Sylvie Brunet; Florence Damond; Jean-Christophe Plantier; Francis Barin
Journal:  J Med Virol       Date:  2015-06-16       Impact factor: 2.327

4.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

5.  Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test.

Authors:  Ilesh V Jani; Bindiya Meggi; Nédio Mabunda; Adolfo Vubil; Nadia E Sitoe; Ocean Tobaiwa; Jorge I Quevedo; Jonathan D Lehe; Osvaldo Loquiha; Lara Vojnov; Trevor F Peter
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

6.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.

Authors:  Ming Chang; Geoffrey S Gottlieb; Joan A Dragavon; Stephen L Cherne; Donna L Kenney; Stephen E Hawes; Robert A Smith; Nancy B Kiviat; Papa Salif Sow; Robert W Coombs
Journal:  J Clin Virol       Date:  2012-07-24       Impact factor: 3.168

7.  9-year HIV-2-associated mortality in an urban community in Bissau, west Africa.

Authors:  A G Poulsen; P Aaby; O Larsen; H Jensen; A Nauclér; I M Lisse; C B Christiansen; F Dias; M Melbye
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

8.  Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Authors:  K M De Cock; G Adjorlolo; E Ekpini; T Sibailly; J Kouadio; M Maran; K Brattegaard; K M Vetter; R Doorly; H D Gayle
Journal:  JAMA       Date:  1993-11-03       Impact factor: 56.272

9.  HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community.

Authors:  Carla van Tienen; Maarten Schim van der Loeff; Ingrid Peterson; Matthew Cotten; Sören Andersson; Birgitta Holmgren; Tim Vincent; Thushan de Silva; Sarah Rowland-Jones; Peter Aaby; Hilton Whittle
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

10.  High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa.

Authors:  Bo Langhoff Hønge; Sanne Jespersen; Johanna Aunsborg; Delfim Vicente Mendes; Candida Medina; David da Silva Té; Alex Lund Laursen; Christian Erikstrup; Christian Wejse
Journal:  Pan Afr Med J       Date:  2016-09-29
View more
  4 in total

1.  Diagnostic tools for tackling febrile illness and enhancing patient management.

Authors:  Konstantinos Mitsakakis; Valérie D'Acremont; Sebastian Hin; Felix von Stetten; Roland Zengerle
Journal:  Microelectron Eng       Date:  2018-10-05       Impact factor: 2.523

2.  Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Authors:  Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2021-02-01       Impact factor: 20.999

3.  Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.

Authors:  Monica Gandhi; Peter Bacchetti; Warren C Rodrigues; Matthew Spinelli; Catherine A Koss; Paul K Drain; Jared M Baeten; Nelly R Mugo; Kenneth Ngure; Leslie Z Benet; Hideaki Okochi; Guohong Wang; Michael Vincent
Journal:  EClinicalMedicine       Date:  2018-08-31

Review 4.  Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV-1 or HIV-2 infection in infants and children aged 18 months or less.

Authors:  Eleanor A Ochodo; Fatuma Guleid; Jonathan J Deeks; Sue Mallett
Journal:  Cochrane Database Syst Rev       Date:  2021-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.